BioSpace News Archive

Perseus Therapeutics, a pioneering biopharmaceutical company based in New York City, is proud to announce the development of a novel thymic stromal lymphopoietin (TSLP) antibody aimed at preventing hair loss in cancer patients and treating a range of inflammatory diseases, including asthma.

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Today, on Wednesday May 22, 2024, IRLAB Therapeutics AB held its Annual General Meeting.

Connect Biopharma Holdings Limited announced that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.

Standard BioTools Inc. (“Standard BioTools”) (Nasdaq:LAB) today announced that its management team will participate in the following investor conferences in the month of June.

89bio, Inc. today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy.

Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed specialty cardiology business.

Quanterix Corporation today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference.

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 2024 Jefferies Healthcare Conference on June 5, 2024.

Biodexa Pharmaceuticals PLC announces $7 million of gross proceeds from the exercise of previously issued warrants and an agreement between the Company and several accredited investors to exercise certain existing Series E warrants and Series F warrants to purchase up to an aggregate of 4,358,322 of the Company’s American Depositary Shares ).

Schrödinger today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference.